Allspring Global Investments Holdings LLC Raises Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Allspring Global Investments Holdings LLC lifted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 224.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,810 shares of the biotechnology company’s stock after acquiring an additional 79,387 shares during the period. Allspring Global Investments Holdings LLC owned 0.43% of Arcturus Therapeutics worth $3,620,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ARCT. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics by 5.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock worth $277,000 after acquiring an additional 606 shares during the period. Great West Life Assurance Co. Can grew its position in Arcturus Therapeutics by 29.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 616 shares during the last quarter. Rhumbline Advisers grew its position in Arcturus Therapeutics by 1.9% in the 3rd quarter. Rhumbline Advisers now owns 36,437 shares of the biotechnology company’s stock valued at $931,000 after buying an additional 675 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Arcturus Therapeutics by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,258 shares of the biotechnology company’s stock worth $266,000 after buying an additional 681 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of Arcturus Therapeutics by 1.4% in the 2nd quarter. Swiss National Bank now owns 52,100 shares of the biotechnology company’s stock worth $1,494,000 after acquiring an additional 700 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 17,435 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $35.02, for a total transaction of $610,573.70. Following the completion of the transaction, the chief operating officer now owns 473,448 shares of the company’s stock, valued at $16,580,148.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.80% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on ARCT shares. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Finally, Citigroup lifted their price target on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.33.

Arcturus Therapeutics Trading Down 1.3 %

Shares of Arcturus Therapeutics stock opened at $25.98 on Friday. The stock has a market cap of $699.25 million, a PE ratio of -24.98 and a beta of 2.60. The company has a 50-day moving average of $35.19 and a two-hundred day moving average of $29.73. Arcturus Therapeutics Holdings Inc. has a 12-month low of $17.52 and a 12-month high of $43.81.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. The company had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. On average, sell-side analysts forecast that Arcturus Therapeutics Holdings Inc. will post -1.42 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.